CAT

925.54

+3.35%↑

300.73

+1.36%↑

GEV.US

1,071.94

+3.08%↑

RTX

178.67

+1.53%↑

238.11

+0.24%↑

CAT

925.54

+3.35%↑

300.73

+1.36%↑

GEV.US

1,071.94

+3.08%↑

RTX

178.67

+1.53%↑

238.11

+0.24%↑

CAT

925.54

+3.35%↑

300.73

+1.36%↑

GEV.US

1,071.94

+3.08%↑

RTX

178.67

+1.53%↑

238.11

+0.24%↑

CAT

925.54

+3.35%↑

300.73

+1.36%↑

GEV.US

1,071.94

+3.08%↑

RTX

178.67

+1.53%↑

238.11

+0.24%↑

CAT

925.54

+3.35%↑

300.73

+1.36%↑

GEV.US

1,071.94

+3.08%↑

RTX

178.67

+1.53%↑

238.11

+0.24%↑

Home・Listă Acțiuni・Ocugen Inc

Ocugen Inc

Închisă

1.47 -2.65

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

1.45

Maxim

1.5899999999999999

Indicatori cheie
By Trading Economics
Venit	2.3M -18M
Vânzări	-1.9M -193K
Marjă de profit	9,174.093
Angajați	116
EBITDA	1.5M -16M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+666.23% upside

Dividende
By Dow Jones
Următoarele câștiguri	31 iul. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-8.7M 626M
Deschiderea anterioară	4.12
Închiderea anterioară	1.47

Scor tehnic

By Trading Central

Încredere

Strong Bearish Evidence

0.6818 / 0.74 Suport & Rezistență

Ocugen Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

11 mai 2026, 22:15 UTC

Achiziții, Fuziuni, Preluări

BMO Financial Group to Sell Transportation-, Vendor-Finance Businesses to Stonepeak

11 mai 2026, 23:46 UTC

Market Talk

Yen Consolidates as Traders Await Bessent's Meetings -- Market Talk

11 mai 2026, 23:44 UTC

Market Talk

Nikkei May Rise on AI Enthusiasm -- Market Talk

11 mai 2026, 23:33 UTC

Market Talk

Gold Rises on Possible Position Adjustments -- Market Talk

11 mai 2026, 22:37 UTC

Market Talk

CSL's Profit, Revenue Downgrade 'Not a Complete Surprise' -- Market Talk

11 mai 2026, 22:32 UTC

Câștiguri

Verde Clean Fuels 1Q Loss/Shr 5c >VGAS

11 mai 2026, 22:02 UTC

Market Talk

Evenimente importante

Stellar Auto Sales Increase in Canada Could Be Tied to Return of EV Incentives -- Market Talk

11 mai 2026, 21:49 UTC

Câștiguri

Rigetti Computing Revenue Triples. Why the Quantum Stock Is Falling. -- Barrons.com

11 mai 2026, 21:42 UTC

Market Talk

Declining Hours Worked Should Keep Bank of Canada Firmly on Hold -- Market Talk

11 mai 2026, 21:32 UTC

Achiziții, Fuziuni, Preluări

Bank of Montreal to Sell Transportation Finance and Vendor Finance Businesses to Stonepeak

11 mai 2026, 21:32 UTC

Achiziții, Fuziuni, Preluări

BMO: Supports Strategy to Elevate Returns and Accelerate Growth, Transaction Accretive to Cap Ratios and ROE >BMO.T

11 mai 2026, 21:32 UTC

Achiziții, Fuziuni, Preluări

BMO: Positions Businesses for Continued Growth in Efficient Cap Structure >BMO.T

11 mai 2026, 21:32 UTC

Achiziții, Fuziuni, Preluări

BMO: To Invest in 19.9% Equity Interest, Enabling Continued Participation in the Businesses' Long-Term Value Creation >BMO.T

11 mai 2026, 21:31 UTC

Achiziții, Fuziuni, Preluări

BMO: Announces Strategic Sale of Transportation and Vendor Finance Businesses

11 mai 2026, 21:23 UTC

Achiziții, Fuziuni, Preluări

CSG Systems Sale to NEC Gets CFIUS Clearance

11 mai 2026, 21:12 UTC

Câștiguri

Ovintiv: Full-Yr Production Volumes Expected to Avg 620 to 645 MBOE/d, Full-Yr Expected Cap Investment of $2.25B to $2.35B >OVV

11 mai 2026, 21:12 UTC

Câștiguri

Ovintiv 1Q Loss/Shr $2.35 >OVV

11 mai 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

11 mai 2026, 20:44 UTC

Câștiguri

Steris: Board Approves New $1B Shr Repurchase Program >STE

11 mai 2026, 20:43 UTC

Câștiguri

Whirlpool Shares Are Still Falling. Last Week's Earnings Might Be Why. -- Barrons.com

11 mai 2026, 20:32 UTC

Câștiguri

CleanSpark 2Q Loss/Shr $1.52 >CLSK

11 mai 2026, 20:32 UTC

Câștiguri

CleanSpark 2Q Rev $136.4M >CLSK

11 mai 2026, 20:30 UTC

Câștiguri

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

11 mai 2026, 20:30 UTC

Câștiguri

Steris 4Q Cont Ops EPS $2.24 >STE

11 mai 2026, 20:30 UTC

Câștiguri

Steris 4Q Rev $1.6B >STE

11 mai 2026, 20:30 UTC

Câștiguri

Steris Sees FY Adj EPS $11.10-Adj EPS $11.30 >STE

11 mai 2026, 20:30 UTC

Câștiguri

Steris 4Q Adj EPS $2.83 >STE

11 mai 2026, 20:22 UTC

Acțiuni populare

Stocks to Watch: Moderna, Intel, Micron, Fox -- WSJ

11 mai 2026, 19:37 UTC

Câștiguri

More Bad News at KKR's Private Credit Fund -- Barrons.com

11 mai 2026, 19:32 UTC

Market Talk

Oil Gains As Trump Rejects Iran's Response to U.S. Plan -- Market Talk

Comparație

Modificare preț

Ocugen Inc Așteptări

Obiectiv de preț

By TipRanks

666.23% sus

Prognoză pe 12 luni

Medie 11.57 USD 666.23%

Maxim 22 USD

Minim 7 USD

În baza a 7 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruOcugen Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

7 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 7 analiști care au acordat evaluări ale acțiunilor Ocugen Inc - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

0.6818 / 0.74Suport & Rezistență

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There are no events.

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.